- Home
- FENG vs SCLX Comparison
FENG vs SCLX Comparison
Compare FENG & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENG
- SCLX
- Stock Information
- Founded
- FENG 1998
- SCLX 2011
- Country
- FENG China
- SCLX United States
- Employees
- FENG N/A
- SCLX N/A
- Industry
- FENG Broadcasting
- SCLX Biotechnology: Pharmaceutical Preparations
- Sector
- FENG Industrials
- SCLX Health Care
- Exchange
- FENG Nasdaq
- SCLX Nasdaq
- Market Cap
- FENG 32.7M
- SCLX 35.7M
- IPO Year
- FENG 2011
- SCLX N/A
- Fundamental
- Price
- FENG $2.80
- SCLX $18.73
- Analyst Decision
- FENG
- SCLX Strong Buy
- Analyst Count
- FENG 0
- SCLX 3
- Target Price
- FENG N/A
- SCLX $367.50
- AVG Volume (30 Days)
- FENG 22.5K
- SCLX 309.9K
- Earning Date
- FENG 11-11-2025
- SCLX 08-13-2025
- Dividend Yield
- FENG N/A
- SCLX N/A
- EPS Growth
- FENG N/A
- SCLX N/A
- EPS
- FENG N/A
- SCLX N/A
- Revenue
- FENG $101,168,374.00
- SCLX $44,236,000.00
- Revenue This Year
- FENG N/A
- SCLX $89.26
- Revenue Next Year
- FENG N/A
- SCLX $203.95
- P/E Ratio
- FENG N/A
- SCLX N/A
- Revenue Growth
- FENG 5.53
- SCLX N/A
- 52 Week Low
- FENG $1.28
- SCLX $3.60
- 52 Week High
- FENG $3.65
- SCLX $39.90
- Technical
- Relative Strength Index (RSI)
- FENG 55.74
- SCLX 46.04
- Support Level
- FENG $2.70
- SCLX $14.80
- Resistance Level
- FENG $2.80
- SCLX $30.90
- Average True Range (ATR)
- FENG 0.17
- SCLX 3.47
- MACD
- FENG -0.02
- SCLX -1.47
- Stochastic Oscillator
- FENG 22.02
- SCLX 23.68
About FENG Phoenix New Media Limited
Phoenix New Media Ltd is a media company providing premium content on an integrated platform across the internet, mobile and TV channels in China. The company organizes its operations into two main segments: Net advertising services and Paid services. It provides its content and services through three channels: ifeng.com channel, video channel, and mobile channel. The company also offers a wide range of paid services including mobile value-added services, games, and content sales. It generates the majority of its revenue from Net advertising services. Geographically, it derives revenue from China.
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.